Ropinirole for restless legs syndrome

A placebo-controlled crossover trial

C. H. Adler, R. A. Hauser, Kapil Dev Sethi, J. N. Caviness, L. Marlor, W. M. Anderson, J. G. Hentz

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

Original languageEnglish (US)
Pages (from-to)1405-1407
Number of pages3
JournalNeurology
Volume62
Issue number8
DOIs
StatePublished - Apr 27 2004

Fingerprint

Restless Legs Syndrome
Cross-Over Studies
Placebos
Dizziness
Nausea
ropinirole
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Adler, C. H., Hauser, R. A., Sethi, K. D., Caviness, J. N., Marlor, L., Anderson, W. M., & Hentz, J. G. (2004). Ropinirole for restless legs syndrome: A placebo-controlled crossover trial. Neurology, 62(8), 1405-1407. https://doi.org/10.1212/01.WNL.0000120672.94060.F1

Ropinirole for restless legs syndrome : A placebo-controlled crossover trial. / Adler, C. H.; Hauser, R. A.; Sethi, Kapil Dev; Caviness, J. N.; Marlor, L.; Anderson, W. M.; Hentz, J. G.

In: Neurology, Vol. 62, No. 8, 27.04.2004, p. 1405-1407.

Research output: Contribution to journalArticle

Adler, CH, Hauser, RA, Sethi, KD, Caviness, JN, Marlor, L, Anderson, WM & Hentz, JG 2004, 'Ropinirole for restless legs syndrome: A placebo-controlled crossover trial', Neurology, vol. 62, no. 8, pp. 1405-1407. https://doi.org/10.1212/01.WNL.0000120672.94060.F1
Adler CH, Hauser RA, Sethi KD, Caviness JN, Marlor L, Anderson WM et al. Ropinirole for restless legs syndrome: A placebo-controlled crossover trial. Neurology. 2004 Apr 27;62(8):1405-1407. https://doi.org/10.1212/01.WNL.0000120672.94060.F1
Adler, C. H. ; Hauser, R. A. ; Sethi, Kapil Dev ; Caviness, J. N. ; Marlor, L. ; Anderson, W. M. ; Hentz, J. G. / Ropinirole for restless legs syndrome : A placebo-controlled crossover trial. In: Neurology. 2004 ; Vol. 62, No. 8. pp. 1405-1407.
@article{03d3128cdebe47e6b75eaf0b5628e50b,
title = "Ropinirole for restless legs syndrome: A placebo-controlled crossover trial",
abstract = "The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.",
author = "Adler, {C. H.} and Hauser, {R. A.} and Sethi, {Kapil Dev} and Caviness, {J. N.} and L. Marlor and Anderson, {W. M.} and Hentz, {J. G.}",
year = "2004",
month = "4",
day = "27",
doi = "10.1212/01.WNL.0000120672.94060.F1",
language = "English (US)",
volume = "62",
pages = "1405--1407",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Ropinirole for restless legs syndrome

T2 - A placebo-controlled crossover trial

AU - Adler, C. H.

AU - Hauser, R. A.

AU - Sethi, Kapil Dev

AU - Caviness, J. N.

AU - Marlor, L.

AU - Anderson, W. M.

AU - Hentz, J. G.

PY - 2004/4/27

Y1 - 2004/4/27

N2 - The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

AB - The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

UR - http://www.scopus.com/inward/record.url?scp=1942537789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942537789&partnerID=8YFLogxK

U2 - 10.1212/01.WNL.0000120672.94060.F1

DO - 10.1212/01.WNL.0000120672.94060.F1

M3 - Article

VL - 62

SP - 1405

EP - 1407

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -